Fully human anti-c-x-c chemokine receptor 3 (cxcr3) antibodies

Abstract

There is disclosed compositions and methods relating to or derived from anti-CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers.

1 .- 7 . (canceled) 
     
     
         8 . A method for treating a subject having cancer, comprising administering an effective amount of an anti-C-X-C chemokine receptor-3 (CXCR3) polypeptide to a subject in need thereof, wherein the anti-CXCR3 polypeptide is selected from the group consisting of a recombinant fully human anti-CXCR3 antibody that binds to CXCR3 a recombinant fully human anti-CXCR3 antibody Fab fragment that binds to CXCR3, and a recombinant anti-CXCR3 single chain antibody that binds to CXCR3, wherein the anti-CXCR3 polypeptide comprises a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO. 17, and comprises a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO. 18. 
     
     
         9 .- 11 . (canceled) 
     
     
         12 . The method of  claim 8 , wherein the cancer is a CXCR3 positive cancer. 
     
     
         13 . The method of  claim 8 , wherein the cancer is selected from the group consisting of carcinoma, leukemia, lymphoma, prostate cancer, non-small cell lung cancer, breast cancer, endometrial cancer, ovarian cancer, gastric cancer, head and neck cancer, melanoma, osteosarcoma, intestinal and colon cancer, and metastatic cancer. 
     
     
         14 .- 18 . (canceled) 
     
     
         19 . A method for treating a subject having cancer, comprising administering an effective amount of a recombinant fully human anti-CXCR3 antibody, or an antigen-binding fragment thereof, that binds to CXCR3, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO: 17; and comprising a light chain variable domain comprising CDRs as set forth in the light chain variable domain amino acid sequence of SEQ ID NO: 18 to the subject having cancer. 
     
     
         20 . The method of  claim 19 , wherein the cancer is selected from the group consisting of carcinoma, leukemia, lymphoma, prostate cancer, non-small cell lung cancer, breast cancer, endometrial cancer, ovarian cancer, gastric cancer, head and neck cancer, melanoma, osteosarcoma, intestinal and colon cancer, and metastatic cancer. 
     
     
         21 . The method of  claim 19 , wherein the recombinant fully human anti-CXCR3 antibody, or antigen-binding fragment thereof, is classified as an isotype selected from the group consisting of: IgG, IgM, IgD, IgA, and IgE. 
     
     
         22 . The method of  claim 21 , wherein the antibody is an IgG1 or an IgG4. 
     
     
         23 . The method of  claim 19 , wherein the recombinant fully human antigen binding fragment is a Fab fragment or a single chain antibody. 
     
     
         24 . The method of  claim 19 , wherein the recombinant fully human anti-CXCR3 antibody, or an antigen-binding fragment thereof, comprises a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO: 17; and comprises a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO: 18. 
     
     
         25 . The method of  claim 19 , wherein the recombinant fully human anti-CXCR3 antibody, or antigen-binding fragment thereof, has a binding affinity of at least 1×10 −6  M. 
     
     
         26 . The method of  claim 19 , wherein the recombinant fully human anti-CXCR3 antibody, or antigen-binding fragment thereof, is an Fab, an Fab′, an F(ab′)2, an Fv, a domain antibody (dAb), a single-chain antibody (scFv), a diabody, a triabody or a tetrabody. 
     
     
         27 . The method of  claim 8 , wherein the recombinant fully human anti-CXCR3 antibody, or recombinant fully human anti-CXCR3 antibody Fab fragment, is classified as an isotype selected from the group consisting of: IgG, IgM, IgD, IgA, and IgE. 
     
     
         28 . The method of  claim 27 , wherein the recombinant fully human anti-CXCR3 antibody or recombinant fully human anti-CXCR3 antibody Fab fragment is an IgG1 or an IgG4. 
     
     
         29 . The method of  claim 8 , wherein the recombinant fully human anti-CXCR3 antibody, or recombinant fully human anti-CXCR3 antibody Fab fragment, has a binding affinity of at least 1×10 −6  M. 
     
     
         30 . The method of  claim 8 , wherein the recombinant fully human anti-CXCR3 antibody, or recombinant fully human anti-CXCR3 antibody Fab fragment, is an Fab, an Fab′, an F(ab′)2, an Fv, a domain antibody (dAb), a single-chain antibody (scFv), a diabody, a triabody or a tetrabody.